Dishman Carbogen Amcis Ltd
DCALDishman Carbogen Amcis Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: annual EPS moved +2,861.9% against a −36.6% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (34 weeks in) while the P/E sits at the 90th percentile of its own 8-year range. Underneath, the last four quarters read deteriorating — profit −352.2% year on year, and 1,031% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Dishman Carbogen Amcis Ltd trades at ₹167, in a downtrend and 34 weeks into that stage. That is −14.5% against its own 200-day average. It sits at 16% of a 52-week range of ₹143 to ₹294. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a downtrend — week 34 of stage 4, confirmed. At ₹167 it trades −14.5% versus its 200-day average and sits at 16% of its 52-week range (₹143–₹294).
Against the market, two honest reads. Cumulative: over the last 9.0 years the stock moved −50% while the NIFTY 500 moved +168% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-09-04) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Dishman Carbogen Amcis Ltd trades at 145.0× P/E, at the pricey end of its own range (90th percentile). Its long-run median P/E is 26.7×, measured across 8.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 145.0× is at the pricey end of its own range (90th percentile), against a long-run median of 26.7× measured over 8.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +2,861.9% against a −36.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +1.0%/yr price move, ~−16.0%/yr came from earnings growth and ~+17.0 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Dishman Carbogen Amcis Ltd was paying for profit growth of about 20.5% a year. Profit itself has compounded 1.3% a year over the past 15 years. Today the market pays 145.0× P/E, the 90th percentile of its own 8-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is far above what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Dishman Carbogen Amcis Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +8.1% | +6.7% | +8.9% | — |
| Profit | +3,133.3% | — | — | — |
| EPS | +2,861.9% | — | — | — |
| Share price | −36.6% | +1.0% | −3.6% | — |
4-Factor Sector Score
22.1/100 — rank 23 of 24 in Pharma - API & CRAMS · 87% evidence confidence
Dishman Carbogen Amcis Ltd scores 22.1 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 23. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 7 + 4.8 + 6.4 + 3.9 = 22.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Dishman Carbogen Amcis Ltd reported ₹678 Cr of revenue in the Jun 26 quarter, −4.2% year on year. Over 15 years it has compounded at 7.2% a year. The last full year, FY26, came in at ₹2,932 Cr. The last four reported quarters add to ₹2,902 Cr.
FY26 revenue came in at ₹2,932 Cr (+8.1% on the year), capping 15 years at 7.2% compound. The latest quarter (Jun 26) printed ₹678 Cr, −4.2% year on year.
Pace check: the last four quarters averaged +0.8% growth against the decade's 7.2% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +0.2% over the last 4 quarters against +9.6%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Dishman Carbogen Amcis Ltd's operating margin is 9.0% in the Jun 26 quarter, −11.0 percentage points against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged 11.0% to 27.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 9.0%, −11.0 pp against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged 11.0%–27.0%.
🚨 Why the margin moved: operating margin went −11.0 pp year on year while gross margin went −3.0 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Dishman Carbogen Amcis Ltd posted a net loss of ₹58.0 Cr in the Jun 26 quarter. Full-year FY26 profit was ₹97.0 Cr. The 15-year compound rate is 1.3%. That loss is 8.6% of the quarter's revenue. The same quarter a year earlier earned ₹23.0 Cr. 6 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹−58.0 Cr, −352.2% year on year. On the full year, FY26 printed ₹97.0 Cr (+3,133.3%), and the 15-year compound rate is 1.3%.
🚨 Why profit moved: revenue contributed −4.2% and the margin −11.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −166.0% vs revenue +0.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 1,031% of Dishman Carbogen Amcis Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹491 Cr of operating cash against ₹97.0 Cr of profit. After ₹1,463 Cr of capital spending, ₹−972 Cr was left as free cash.
FY26: operating cash of ₹491 Cr against reported profit of ₹97.0 Cr, leaving free cash of ₹−972 Cr after ₹1,463 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 1,031% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 1,031%: the cash cycle stretched 455 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 2.5× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Dishman Carbogen Amcis Ltd's cash conversion cycle runs 805 days in FY26, up from 350 days in FY21. Capital spending ran ₹2,359 Cr over the last 3 years. At FY26 sales of ₹2,932 Cr each day of that cycle holds about ₹8.0 Cr, so roughly ₹6,466 Cr sits inside the business at any moment.
FY26: debtors at 84 days, inventory at 910 days — roughly 29.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 805 days, looser than FY21's 350.
The full loop: cash goes out to suppliers and production on day 0; stock waits 910 days to sell; customers pay about 84 days after that; and suppliers themselves are paid at 189 days — netting out to the 805-day cycle.
In money terms: at FY26 sales of ₹2,932 Cr, each day of the cycle holds about ₹8.0 Cr — so the 805-day loop keeps roughly ₹6,466 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹2,359 Cr over the last 3 fiscal years against ₹944 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹570 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Dishman Carbogen Amcis Ltd earns a ROCE of 3% in FY26. That is up from a trough of 0% in FY21. Return on invested capital clears the cost of that capital by −10.4 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 3.3% net margin on 0.25× asset turns.
FY26 ROCE is 3%, recovered from a FY21 trough of 0% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 3.3% net margin × 0.25× asset turns × 1.78× balance-sheet leverage ≈ 1.5% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 1.6% − 12.0% = a −10.4 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Dishman Carbogen Amcis Ltd carries total debt of ₹3,076 Cr against shareholder equity of ₹6,677 Cr as of Mar 26, a debt-to-equity of 0.46. On the annual view that ratio went from 0.33 in FY22 to 0.46 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹3,076 Cr against shareholder equity of ₹6,677 Cr — a debt-to-equity of 0.46. On the annual view, debt-to-equity went from 0.33 (FY22) to 0.46 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 1.2 points of Dishman Carbogen Amcis Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 6.9% of the company. Domestic institutions moved +0.6 points over the same window, to 2.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −1.2 points over 8 quarters to 6.9%; Domestic institutions: +0.6 points over 8 quarters to 2.1%; Promoters: +0.0 points over 8 quarters to 59.3%.
🚨 Why the register moved: foreign institutions drove it (−1.2 points), absorbed on the other side by domestic institutions (+0.6 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Dishman Carbogen Amcis Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Neuland Laboratories LtdNEULANDLAB | 81.2/100Sector-leading setup100% evidence | LEADER | 33.6/35 Revenue 78.3% · PAT 100% · OPM change 23 pp 100% evidence | 19.9/25 ROCE 26.5% · OPM 35% 100% evidence | 12.0/20 P/E 60.7× · PEG 1.05 100% evidence | 15.7/20 RS sector 7.5% · RS bench 44.6% · 1Y 62.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 33.6 + 19.9 + 12 + 15.7 = 81.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Acutaas Chemicals LtdACUTAAS | 77.3/100Favorable setup76% evidence | 31.9/35 Revenue 41% · PAT 100% · OPM change 9 pp 95% evidence | 20.1/25 ROCE 31.6% · OPM 34% 76% evidence | 9.3/20 P/E 71.7× · PEG — 50% evidence | 16.0/20 RS sector 86.5% · RS bench 43.7% · 1Y 129.5%5 of 8 weeks ahead 70% evidence | |
| Exact sum: 31.9 + 20.1 + 9.3 + 16 = 77.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3IOL Chemicals & Pharmaceuticals LtdIOLCP | 73.0/100Favorable setup100% evidence | LEADER | 28.5/35 Revenue 18.5% · PAT 60% · OPM change 3 pp 100% evidence | 12.5/25 ROCE 11.3% · OPM 14% 100% evidence | 13.8/20 P/E 32.3× · PEG 0.66 100% evidence | 18.2/20 RS sector 37.2% · RS bench 81.2% · 1Y 100.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.5 + 12.5 + 13.8 + 18.2 = 73 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Laurus Labs LtdLAURUSLABS | 71.2/100Favorable setup93% evidence | LEADER | 32.2/35 Revenue 22.6% · PAT 100% · OPM change 8 pp 100% evidence | 18.2/25 ROCE 17.8% · OPM 32% 100% evidence | 5.3/20 P/E 97.3× · PEG 3.33 65% evidence | 15.5/20 RS sector 22.2% · RS bench 63.4% · 1Y 123.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.2 + 18.2 + 5.3 + 15.5 = 71.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Gland Pharma LtdGLAND | 69.7/100Favorable setup100% evidence | LEADER | 26.4/35 Revenue 17.6% · PAT 46.4% · OPM change 3 pp 100% evidence | 13.9/25 ROCE 15.1% · OPM 27% 100% evidence | 14.2/20 P/E 42.1× · PEG 1.45 100% evidence | 15.2/20 RS sector 8.2% · RS bench 45.5% · 1Y 54.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 13.9 + 14.2 + 15.2 = 69.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Divis Laboratories LtdDIVISLAB | 65.4/100Favorable setup100% evidence | LEADER | 26.5/35 Revenue 16.4% · PAT 26.8% · OPM change 11 pp 100% evidence | 19.1/25 ROCE 22% · OPM 41% 100% evidence | 3.5/20 P/E 83.1× · PEG 3.45 100% evidence | 16.3/20 RS sector 3.2% · RS bench 39.9% · 1Y 55.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 26.5 + 19.1 + 3.5 + 16.3 = 65.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 7Shilpa Medicare LtdSHILPAMED | 63.1/100Mixed-positive evidence100% evidence | LEADER | 27.6/35 Revenue 28% · PAT 100% · OPM change 1 pp 100% evidence | 10.3/25 ROCE 10.9% · OPM 29% 100% evidence | 5.6/20 P/E 66.1× · PEG 6.86 100% evidence | 19.6/20 RS sector 60.8% · RS bench 111.5% · 1Y 127.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.6 + 10.3 + 5.6 + 19.6 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Sai Life Sciences LtdSAILIFE | 62.9/100Mixed-positive evidence93% evidence | LEADER | 27.2/35 Revenue 17.6% · PAT 48% · OPM change 3 pp 100% evidence | 16.6/25 ROCE 19.6% · OPM 27% 100% evidence | 4.9/20 P/E 91.6× · PEG 3.46 65% evidence | 14.2/20 RS sector 12.7% · RS bench 51.7% · 1Y 84.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 16.6 + 4.9 + 14.2 = 62.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 9Granules India LtdGRANULES | 62.4/100Mixed-positive evidence100% evidence | LEADER | 26.4/35 Revenue 24.8% · PAT 38.1% · OPM change 3 pp 100% evidence | 15.8/25 ROCE 15.5% · OPM 23% 100% evidence | 10.4/20 P/E 34.7× · PEG 1.27 100% evidence | 9.8/20 RS sector 1.7% · RS bench 37.1% · 1Y 77.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 15.8 + 10.4 + 9.8 = 62.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Windlas Biotech LtdWINDLAS | 53.5/100Mixed-positive evidence77% evidence | BREAKING OUT | 16.7/35 Revenue 18.8% · PAT 9.8% · OPM change -2 pp 83% evidence | 14.5/25 ROCE 15.9% · OPM 11% 95% evidence | 11.5/20 P/E 35.1× · PEG — 50% evidence | 10.8/20 RS sector -1.8% · RS bench 34.7% · 1Y 13.7%5 of 10 weeks ahead 70% evidence |
| Exact sum: 16.7 + 14.5 + 11.5 + 10.8 = 53.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Anthem Biosciences LtdANTHEM | 53.0/100Mixed-positive evidence77% evidence | BREAKING OUT | 12.7/35 Revenue -2.1% · PAT 14.1% · OPM change 1 pp 100% evidence | 22.0/25 ROCE 30.4% · OPM 36% 100% evidence | 9.2/20 P/E 89.3× · PEG — 15% evidence | 9.1/20 RS sector -4.6% · RS bench 29.4% · 1Y 13.4%7 of 12 weeks ahead 70% evidence |
| Exact sum: 12.7 + 22 + 9.2 + 9.1 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12SMS Pharmaceuticals LtdSMSPHARMA | 48.7/100Mixed-negative evidence100% evidence | TURNING | 19.1/35 Revenue 10.2% · PAT 41.7% · OPM change 0 pp 100% evidence | 11.3/25 ROCE 13.3% · OPM 20% 100% evidence | 10.3/20 P/E 42.4× · PEG 1.53 100% evidence | 8.0/20 RS sector -2.8% · RS bench 32.7% · 1Y 96.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 11.3 + 10.3 + 8 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Morepen Laboratories LtdMOREPENLAB | 48.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 20.3/35 Revenue 9.5% · PAT 51.6% · OPM change 8 pp 100% evidence | 8.5/25 ROCE 8.1% · OPM 14% 100% evidence | 9.7/20 P/E 54× · PEG 1.68 100% evidence | 10.0/20 RS sector -16.2% · RS bench 130.1% · 1Y 134.8%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.3 + 8.5 + 9.7 + 10 = 48.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Blue Jet Healthcare LtdBLUEJET | 46.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 5.8/35 Revenue -27.5% · PAT -34.6% · OPM change -1 pp 100% evidence | 21.0/25 ROCE 26.1% · OPM 33% 100% evidence | 13.8/20 P/E 45.8× · PEG 1.39 100% evidence | 5.9/20 RS sector -39.2% · RS bench 12% · 1Y -23.6%10 of 10 weeks ahead 70% evidence |
| Exact sum: 5.8 + 21 + 13.8 + 5.9 = 46.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 15Supriya Lifescience LtdSUPRIYA | 45.3/100Mixed-negative evidence100% evidence | FADING | 16.1/35 Revenue 28.2% · PAT 11.2% · OPM change -11 pp 100% evidence | 17.1/25 ROCE 25.2% · OPM 25% 100% evidence | 6.9/20 P/E 36.5× · PEG 3.11 100% evidence | 5.2/20 RS sector -11.2% · RS bench 20.4% · 1Y 38.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 17.1 + 6.9 + 5.2 = 45.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 16Concord Biotech LtdCONCORDBIO | 37.8/100Mixed-negative evidence94% evidence | BREAKING OUT | 9.2/35 Revenue -6.7% · PAT -23.3% · OPM change 2 pp 100% evidence | 14.9/25 ROCE 17.1% · OPM 32% 100% evidence | 6.7/20 P/E 56.7× · PEG 5.67 100% evidence | 7.0/20 RS sector -23.6% · RS bench 16.4% · 1Y -9.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 9.2 + 14.9 + 6.7 + 7 = 37.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Jubilant Pharmova LtdJUBLPHARMA | 37.6/100Mixed-negative evidence93% evidence | TURNING | 11.8/35 Revenue 16.3% · PAT -23% · OPM change -4 pp 100% evidence | 6.8/25 ROCE 9% · OPM 11% 100% evidence | 13.9/20 P/E 42.1× · PEG 1.17 65% evidence | 5.1/20 RS sector -23% · RS bench 5.6% · 1Y -4.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 6.8 + 13.9 + 5.1 = 37.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18Piramal Pharma LtdPPLPHARMA | 35.2/100Mixed-negative evidence71% evidence | LEADER | 13.0/35 Revenue 0.8% · PAT -80% · OPM change 3 pp 74% evidence | 1.4/25 ROCE 2.5% · OPM 9% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.8/20 RS sector -10.9% · RS bench 21.1% · 1Y 5.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 1.4 + 10 + 10.8 = 35.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Solara Active Pharma Sciences LtdSOLARA | 34.7/100Adverse evidence83% evidence | TURNING | 7.9/35 Revenue 15.6% · PAT -80% · OPM change -2 pp 100% evidence | 3.8/25 ROCE 4.9% · OPM 16% 100% evidence | 8.5/20 P/E 843× · PEG — 15% evidence | 14.5/20 RS sector 1.9% · RS bench 38.7% · 1Y 12.7%8 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 3.8 + 8.5 + 14.5 = 34.7 · Decision use: Price leads the evidence: RS versus the benchmark is 38.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Hikal LtdHIKAL | 33.0/100Adverse evidence81% evidence | BREAKING OUT | 11.6/35 Revenue -5.4% · PAT -80% · OPM change 2.6 pp 74% evidence | 4.3/25 ROCE 3.5% · OPM 9.2% 100% evidence | 7.4/20 P/E 65.4× · PEG — 50% evidence | 9.7/20 RS sector -21.7% · RS bench 6.9% · 1Y -14.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 4.3 + 7.4 + 9.7 = 33 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21OneSource Specialty Pharma LtdONESOURCE | 27.5/100Adverse evidence71% evidence | BASING | 11.3/35 Revenue 4.3% · PAT -80% · OPM change 0 pp 74% evidence | 3.3/25 ROCE 0.6% · OPM 27% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.9/20 RS sector -27.3% · RS bench -0.8% · 1Y -15%3 of 12 weeks ahead 100% evidence |
| Exact sum: 11.3 + 3.3 + 10 + 2.9 = 27.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Syngene International LtdSYNGENE | 23.6/100Adverse evidence100% evidence | BASING | 6.7/35 Revenue -3.4% · PAT -56.4% · OPM change -11.3 pp 100% evidence | 8.6/25 ROCE 10% · OPM 12.3% 100% evidence | 8.1/20 P/E 52.2× · PEG 7.87 100% evidence | 0.2/20 RS sector -44.2% · RS bench -22.8% · 1Y -41%1 of 12 weeks ahead 100% evidence |
| Exact sum: 6.7 + 8.6 + 8.1 + 0.2 = 23.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Dishman Carbogen Amcis Ltdthis pageDCAL | 22.1/100Adverse evidence87% evidence | ASLEEP | 7.0/35 Revenue 0.2% · PAT -80% · OPM change -11 pp 100% evidence | 4.8/25 ROCE 3.1% · OPM 9% 100% evidence | 6.4/20 P/E 145× · PEG 2.65 65% evidence | 3.9/20 RS sector -31% · RS bench -18.6% · 1Y -39.5%3 of 10 weeks ahead 70% evidence |
| Exact sum: 7 + 4.8 + 6.4 + 3.9 = 22.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Cohance Lifesciences LtdCOHANCE | 20.6/100Adverse evidence82% evidence | BREAKING OUT | 3.0/35 Revenue -19.8% · PAT -80% · OPM change -19.7 pp 95% evidence | 6.8/25 ROCE 5.8% · OPM 0.3% 76% evidence | 5.5/20 P/E 156× · PEG — 50% evidence | 5.3/20 RS sector -33.4% · RS bench -9.2% · 1Y -52.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 3 + 6.8 + 5.5 + 5.3 = 20.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Dishman Carbogen Amcis Ltd's share price today?
Dishman Carbogen Amcis Ltd trades at ₹167, −36.6% over the past year. The company is valued at ₹2,622 Cr. The stock sits at 16% of its 52-week range of ₹143–₹294, −14.5% versus its 200-day average. On the tape, the price is in a downtrend, 34 weeks in. — as of 11 September 2026.
What were Dishman Carbogen Amcis Ltd's latest quarterly results?
Dishman Carbogen Amcis Ltd reported revenue of ₹678 Cr and a net loss of ₹58.0 Cr for the Jun 26 quarter. Revenue fell 4.2% and profit fell 352.2% year on year. Earnings per share were ₹−3.69. The operating margin was 9.0%, 11.0 pp lower than a year earlier. — as of 11 September 2026.
What is Dishman Carbogen Amcis Ltd's revenue?
Dishman Carbogen Amcis Ltd reported revenue of ₹678 Cr in the Jun 26 quarter, −4.2% year on year. For the full FY26 fiscal year, revenue was ₹2,932 Cr (+8.1%). Over the last 15 years revenue compounded at 7.2% a year. — as of 11 September 2026.
What is Dishman Carbogen Amcis Ltd's profit?
Dishman Carbogen Amcis Ltd earned ₹−58.0 Cr of net profit in the Jun 26 quarter, −352.2% year on year. Full-year FY26 profit was ₹97.0 Cr. The operating margin ran 9.0% in the latest quarter. — as of 11 September 2026.
What is Dishman Carbogen Amcis Ltd's market cap?
Dishman Carbogen Amcis Ltd's market capitalisation is ₹2,622 Cr at a share price of ₹167. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Dishman Carbogen Amcis Ltd's P/E ratio?
Dishman Carbogen Amcis Ltd trades at a P/E of 145.0×, at the 90th percentile of its own 8-year range, against a long-run median of 26.7×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Dishman Carbogen Amcis Ltd pay a dividend?
Not in its latest year — Dishman Carbogen Amcis Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 1 of its last 11 reported fiscal years, so there is a history but no current dividend. — as of 11 September 2026.
Is Dishman Carbogen Amcis Ltd overvalued?
On its own history, Dishman Carbogen Amcis Ltd looks expensive: its P/E of 145.0× sits at the 90th percentile of its 8-year range (long-run median 26.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Dishman Carbogen Amcis Ltd growing?
Not right now — Dishman Carbogen Amcis Ltd's latest numbers are shrinking: latest-quarter revenue −4.2% year on year, profit −352.2%, and the margin −11.0 pp at 9.0%. The 15-year compound rates are 7.2% (revenue) and 1.3% (profit). The earnings engine currently reads: deteriorating — as of 11 September 2026.
How is Dishman Carbogen Amcis Ltd performing?
Dishman Carbogen Amcis Ltd is in a downtrend, 34 weeks in. Its latest quarter's revenue fell 4.2% and profit fell 352.2% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 11 September 2026.
Is Dishman Carbogen Amcis Ltd in an uptrend?
No — the price is in a downtrend (week 34 of stage 4), trading −14.5% versus its 200-day average and at 16% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Dishman Carbogen Amcis Ltd beating the market?
Not lately — on a trailing-13-week view Dishman Carbogen Amcis Ltd is currently behind the NIFTY 500 (1 week and counting; last ahead the week of 2026-09-04), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 9.0 years the stock moved −50% against the NIFTY 500's +168% — behind the index over the full window. — as of 11 September 2026.
Will Dishman Carbogen Amcis Ltd's share price go up?
This page publishes no price forecast for Dishman Carbogen Amcis Ltd. What it measures instead: the share price is ₹167, the price is in a downtrend 34 weeks in. Its P/E of 145.0× sits at the 90th percentile of its own 8-year range. — as of 11 September 2026.
Who owns Dishman Carbogen Amcis Ltd?
Promoters hold 59.3% of Dishman Carbogen Amcis Ltd, foreign institutions 6.9%, domestic institutions 2.1% and the public 31.8% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 1.2 points over 8 quarters. — as of 11 September 2026.
Does Dishman Carbogen Amcis Ltd have too much debt?
It is moderate — Dishman Carbogen Amcis Ltd's debt-to-equity is 0.46, and operating profit covers the interest bill 3×. FY26 borrowings were ₹3,076 Cr against equity of ₹6,677 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is Dishman Carbogen Amcis Ltd's capex?
Dishman Carbogen Amcis Ltd spent ₹2,359 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹1,463 Cr, with ₹570 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Dishman Carbogen Amcis Ltd's cash flow?
Dishman Carbogen Amcis Ltd generated ₹491 Cr of operating cash flow in FY26 and ₹−972 Cr of free cash flow after ₹1,463 Cr of capital spending. Reported profit that year was ₹97.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Dishman Carbogen Amcis Ltd's profit real cash?
Yes — over the last 3 fiscal years, 1,031% of Dishman Carbogen Amcis Ltd's reported profit arrived as operating cash. Though the latest year ran at 506% — the trend is the thing to watch. In FY26, operating cash was ₹491 Cr against reported profit of ₹97.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Dishman Carbogen Amcis Ltd in its business cycle?
Dishman Carbogen Amcis Ltd's FY26 operating margin was 19.0%, against a 11-year band of 11.0%–27.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 9.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Dishman Carbogen Amcis Ltd's price assume?
At its price on 13 June 2026, Dishman Carbogen Amcis Ltd was priced for profit growth of about 20.5% a year. Profit itself has compounded 1.3% a year over the past 15 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Dishman Carbogen Amcis Ltd story?
The sharpest disagreement: annual EPS moved +2,861.9% against a −36.6% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Dishman Carbogen Amcis Ltd a stock worth studying right now?
This is not investment advice. The machine read: Dishman Carbogen Amcis Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!